Kari Kendra

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.104Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004

Top 78%

0.104DataRank

Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

Papers

Driven by 37 papers — median percentile 11. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763

N/A

5.4DataRank · unranked

446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002478

N/A

4.0DataRank · unranked

140 citations

Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl +24 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Cancer(2024)10.1002/cncr.35200

N/A

0.612DataRank · unranked

12 citations

James Moon, Christopher D. Lao, Bartosz Chmielowski, Kari Kendra, Karl D. Lewis +12 more

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002535

N/A

0.520DataRank · unranked

31 citations

Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid +16 more

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9502

N/A

0.464DataRank · unranked

21 citations

James Moon, Zeynep Eroglu, Siwen Hu‐Lieskovan, William E. Carson, David A. Wada +15 more

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

The Oncologist(2023)10.1093/oncolo/oyad097

N/A

0.406DataRank · unranked

14 citations

Mike Yang, Lai Wei, Madison Grogan, Daniel Spakowicz, Sandipkumar Patel +10 more

Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03373-y

N/A

0.396DataRank · unranked

13 citations

Maria Riley, Songzhu Zhao, Jing Gennie Wang, Vince Esguerra, Mingjia Li +8 more

Inhibition of Bruton’s tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors

JCI Insight(2024)10.1172/jci.insight.169927

N/A

0.312DataRank · unranked

6 citations

Brooke Benner, Robert Wesolowski, Dionisia Quiroga, Logan Good, Steven Sun +27 more

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9511

N/A

0.239DataRank · unranked

3 citations

Janice M. Mehnert, Anita Giobbie‐Hurder, Kari Kendra, Gino K. In, April K.S. Salama +14 more

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9559

N/A

0.165DataRank · unranked

2 citations

Yue Zheng, Michael B. Atkins, Bartosz Chmielowski, Ahmad A. Tarhini, Thach‐Giao Truong +14 more

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004

Top 78%

0.104DataRank

Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

442 Pre-treatment interstitial abnormalities is a risk factor for immune checkpoint inhibitor pneumonitis in patients with lung cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0442

N/A

0DataRank · unranked

0 citations

Maria Riley, Songzhu Zhao, Jessica Zimmer, Matthew Viveiros, Jing Gennie Wang +10 more

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03497-1

N/A

0DataRank · unranked

15 citations

Colin D. Angell, Himanshu Savardekar, Debasish Sundi, David Abood, Brooke Benner +15 more

Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03371-0

N/A

0DataRank · unranked

11 citations

Mike Yang, Lai Wei, Madison Grogan, Sandipkumar Patel, Mingjia Li +9 more

Data from Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α

(2023)10.1158/1078-0432.c.6516939

N/A

0DataRank · unranked

0 citations

Gregory B. Lesinski, Amy S. Ruppert, Michael D. Radmacher, Carl Noble, Kari Kendra +3 more

Data from Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α

(2023)10.1158/1078-0432.c.6516939.v1

N/A

0DataRank · unranked

0 citations

Gregory B. Lesinski, Amy S. Ruppert, Michael D. Radmacher, Carl Noble, Kari Kendra +3 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review

PLoS ONE(2024)10.1371/journal.pone.0297531

N/A

0DataRank · unranked

18 citations

Heather Armbruster, Gretchen Pardo, Brianna Archambeau, Na Hyun Kim, Joanne Jeter +9 more

BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy

Journal of Clinical Investigation(2025)10.1172/jci181975

N/A

0DataRank · unranked

6 citations

Andrew Stiff, Alvin Liu, Robert Wesolowski, Emily Schwarz, Ian C. Garbarine +23 more

Impact of age‐related T‐cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: A prospective cohort study

Aging and Cancer(2020)10.1002/aac2.12012

N/A

0DataRank · unranked

1 citations

Andrea M. Holderbaum, Namrata Arya, Suohui Zhang, Michael S. Bodnar, Ruthann Norman +5 more

A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade

Melanoma Research(2025)10.1097/cmr.0000000000001023

N/A

0DataRank · unranked

0 citations

Steven Sun, Gabriella Lapurga, Brooke Benner, Dionisia Quiroga, Himanshu Savardekar +11 more

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10039

N/A

0DataRank · unranked

1 citations

Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry +15 more

Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10059

N/A

0DataRank · unranked

0 citations

Megan Othus, Benjamin Newell Voorhies, Kari Kendra, Shaker R. Dakhil, Amy Harker-Murray +6 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-03068-2

N/A

0DataRank · unranked

47 citations

Songzhu Zhao, Mingjia Li, Sandip H. Patel, Andrew Johns, Madison Grogan +13 more

Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.02.002

N/A

0DataRank · unranked

42 citations

Lai Wei, Madison Grogan, Rebecca Hoyd, John F. P. Bridges, Sandipkumar Patel +12 more

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma

Frontiers in Immunology(2021)10.3389/fimmu.2021.740890

N/A

0DataRank · unranked

38 citations

Brooke Benner, Himanshu Savardekar, Gabriella Lapurga, Logan Good, David Abood +13 more

BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma

Radiation Oncology(2021)10.1186/s13014-021-01903-5

N/A

0DataRank · unranked

11 citations

Priyanka Chablani, Michael Siedow, Eric D. Miller, Steve Walston, Kari Kendra +3 more

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.36_suppl.356154

N/A

0DataRank · unranked

111 citations

Sandra J. Lee, Bartosz Chmielowski, Antoni Ribas, Ahmad A. Tarhini, Thach‐Giao Truong +9 more

Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2633

N/A

0DataRank · unranked

11 citations

Menglin Xu, Sandipkumar Patel, Andrew Johns, Madison Grogan, Mingjia Li +13 more

Immune checkpoint inhibitor induced hepatitis: Risk factors, outcomes, and impact on survival.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e14525

N/A

0DataRank · unranked

2 citations

Songzhu Zhao, Sandip H. Patel, Andrew Johns, Madison Grogan, Mingjia Li +9 more

686 Characterization of a novel compound that inhibits peroxynitrite generation by myeloid derived suppressor cells

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.686

N/A

0DataRank · unranked

1 citations

Steven Sun, Erick J. Carlson, Himanshu Savardekar, Kari Kendra, Blake R. Peterson +2 more

Early changes in lymphocyte/monocyte ratio on-treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitors

Research Square(2021)10.21203/rs.3.rs-758097/v1

Top 100%

0DataRank

Top 100%0 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +14 more

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

Journal of Cancer Research and Clinical Oncology(2022)10.1007/s00432-022-04340-3

N/A

0DataRank · unranked

40 citations

Gabriel Tinoco, Songzhu Zhao, Lai Wei, Andrew Johns, Sandip Pravin Patel +14 more

Kari Kendra

Indexed papers

Top data-sharing exemplar

Papers